Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma
BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korea...
DB Group eyes Hanyang Securities amid KCGI deal uncertainty
DB Group, which owns DB Securities Co. and DB Insurance Co., is considering acquiring Hanyang Securities Co., as a deal by South Korean private equi...
Samsung Biologics bags $514 mn CMO contract from US pharma
Samsung Biologics Co., the world’s largest contract manufacturing organization (CMO), said on Monday it has secured a $5.14 million order from...
Samsung Biologics signs $1.4 bn CMO deal with European pharma
South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, said on Tuesday it signed a $1.4 billion contract manufacturing o...
KCGI buys control of Hanyang Securities for $166 mn
KCGI, a South Korean private equity firm, has agreed to buy a controlling stake in Hanyang Securities Co. for 220.3 billion won ($166 million), slig...
Activst fund KCGI struggles to fund Hanyang Securities deal
KCGI, a South Korean private equity firm, has been struggling to raise funds for its 244.9-billion-won ($183 million) purchase of a controlling stak...
Activist fund KCGI to buy Hanyang Securities for $180 mn
South Korean private equity firm KCGI Co. is expected to acquire local brokerage house Hanyang Securities Co. for 244.9 billion won ($179.8 million)...
Hanyang Securities stake draws bids without sale manager
Hanyang Securities Co. has received preliminary bids from four to five South Korean companies or consortia for its 11.3% stake after its controlling...
Hanyang Securities up for sale; in talks with KCGI, Woori
Hanyang Securities Co., a small South Korean brokerage firm, has been put on the market as its parent Hanyang University Foundation scrambles to kee...
Samsung’s biotech duo on a roll with $1.1 bn CMO order
Samsung Group is on track to rise to the top of biosimilar companies in the world and become South Korea’s largest drug maker for contract man...
Samsung Biologics reaches record-breaking annual orders
Samsung Biologics Co., the world’s top contract manufacturing organization (CMO) by capacity, surpassed the annual contract manufacturing orde...
Hyundai Group chair exits Schindler-invested unit board
Hyundai Group's chairwoman on Friday resigned from the board of its elevator unit, whose No. 2 shareholder is Schindler Holding AG, amid mounting sh...
KCGI Asset Management appoints former KIS head as new CMO
South Korea’s KCGI Asset Management, formerly Meritz Asset Management, announced on Friday that it has hired Cho Won-bok, former division head...
SK Bioscience buys 6.5 million Novavax shares for $83.4 million
SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Wednesday it has signed a deal to buy 6.5 million shares in US vacc...
KCGI’s ascent to intensify family feud over DB control; DB stocks rally
A sibling feud over management control of DB Group is expected to intensify following the ascent of South Korean activist fund Korea Corporate Gover...
S.Korean activist fund KCGI eyes foundry DB HiTek buyout
Korea Corporate Governance Improvement Fund (KCGI) is eyeing a controlling stake in DB HiTek Co. as the activist fund became the second-largest shar...
Chip foundry DB HiTek's stock near 10-month peak on activist fund
South Korean leading foundry chipmaker DB HiTek’s stock price hit a near 10-month high this week as a domestic activist fund bought a stake to...
Samsung Biologics bags $183 million CMO order from Pfizer
Samsung Biologics Co., the world’s No. 1 contract drug maker in terms of production capacity, has won a $182.7 million contract manufacturing ...
Brazil approves Celltrion Pharm’s syringe facility
Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...
Activist fund KCGI to sell Osstem stake to UCK, MBK Partners
Korea Corporate Governance Improvement Fund (KCGI), one of the country’s most aggressive shareholder activists, plans to sell its stake in Oss...
MBK, Unison to expand Osstem Implant's target reach beyond China
South Korean private equity firm Unison Capital Korea is set to focus on boosting the corporate value of Osstem Implant Co., once the PE manager and...
Korean activist fund KCGI buys Meritz Asset Management
A consortium led by Korea Corporate Governance Improvement Fund (KCGI), a local activist fund, said on Jan. 9 it signed a share purchase agreement l...
Korea's Meritz Group likely to sell off its asset management arm
South Korea’s Meritz Financial Group Inc. is poised to sell off its subsidiary Meritz Asset Management Co., The Korea Economic Daily understoo...
Korea's Samsung Biologics signs $296 mn CMO deal with GSK
South Korea’s Samsung Biologics Co. has signed a $296.1 million deal to supply biopharmaceutical products to UK-based multinational pharma gia...
Samsung Biologics signs $81 mn CMO deal with Novartis
South Korea’s Samsung Biologics Co. has inked an $81 million contract manufacturing deal with Novartis, the world’s fifth-largest pharma...
Lessons learned from activist fund’s KAL exit
Activist fund Korea Corporate Governance Improvement Fund (KCGI) recently exited its investment in Hanjin KAL Co., the parent company of Korean Air ...
SK seeks to make Pfizer, Merck COVID-19 pills in CMO deals
SK Inc., the investment and holding company of South Korea’s SK Group, is seeking to make COVID-19 treatment pills developed by Pfizer Inc. an...
Korea’s Genome & Company aims US CMO market
South Korea’s microbiome medicine developer Genome & Company geared up for entering the U.S. market to boost profits and make inroads into...
Korean activist fund KCGI joins in consortium to buy Ssangyong
A South Korean electric bus maker Edison Motors Co. added the activist fund Korea Corporate Government Improvement Fund (KCGI) as a financial invest...
CureVac may pick Korea as Asian base for COVID vaccine production
German biopharmaceutical company CureVac N.V. may choose South Korea as one of its global production bases for the COVID-19 vaccine following Korean...
